ProKidney Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

ProKidney şirketinin toplam hissedar öz sermayesi $443.5M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $474.8M ve $31.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$406.81m
Eşitlik	US$443.47m
Toplam yükümlülükler	US$31.33m
Toplam varlıklar	US$474.79m

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About ProKidney's (NASDAQ:PROK) Cash Burn Situation

Nov 17

ProKidney (NASDAQ:PROK) Is In A Strong Position To Grow Its Business

Mar 14

Recent updates

We're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash Wisely

Nov 18

We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate

Aug 12

We Think ProKidney (NASDAQ:PROK) Can Afford To Drive Business Growth

May 12

Here's Why We're Not Too Worried About ProKidney's (NASDAQ:PROK) Cash Burn Situation

Nov 17

ProKidney (NASDAQ:PROK) Is In A Strong Position To Grow Its Business

Mar 14

ProKidney reports Q2 2022 results

Aug 11

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: PROK 'nin kısa vadeli varlıkları ( $430.2M ) kısa vadeli yükümlülüklerini ( $25.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: PROK şirketinin kısa vadeli varlıkları ( $430.2M ) uzun vadeli yükümlülüklerini ( $6.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: PROK borçsuzdur.

Borcun Azaltılması: PROK un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: PROK şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: PROK serbest nakit akışı her yıl % 24.2 2.1 yıl yetecek nakit akışına sahip olacaktır.

ProKidney Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash Wisely

We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate

We Think ProKidney (NASDAQ:PROK) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About ProKidney's (NASDAQ:PROK) Cash Burn Situation

ProKidney (NASDAQ:PROK) Is In A Strong Position To Grow Its Business

Recent updates

We're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash Wisely

Prokidney Corp. Reports Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Prokidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S

New minor risk - Shareholder dilution

We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate

New minor risk - Shareholder dilution

ProKidney Corp. has completed a Follow-on Equity Offering in the amount of $26.693989 million.

New minor risk - Shareholder dilution

ProKidney Corp. Announces Positive Interim Regen-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

Price target decreased by 24% to US$4.83

Chief Reg. Off notifies of intention to sell stock

We Think ProKidney (NASDAQ:PROK) Can Afford To Drive Business Growth

ProKidney Corp., Annual General Meeting, May 30, 2024

New major risk - Share price stability

Chief Reg. Off notifies of intention to sell stock

ProKidney Corp. Announces Key Leadership Appointments Strengthening Clinical and Technical Operations

New major risk - Revenue and earnings growth

New minor risk - Market cap size

ProKidney Corp. Announces Termination of Deepak Jain as Chief Operating Officer

Prokidney Appoints Nikhil Pereira-Kamath as Chief Business Officer

ProKidney Corp. (NasdaqCM:PROK) announces an Equity Buyback for 7,256,367 shares, for $9.5 million.

New major risk - Revenue and earnings growth

Here's Why We're Not Too Worried About ProKidney's (NASDAQ:PROK) Cash Burn Situation

Price target decreased by 19% to US$12.50

ProKidney Corp. Announces Executive Changes

ProKidney Corp. Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 22%

Investor sentiment deteriorates as stock falls 20%

Investor sentiment deteriorates as stock falls 20%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

ProKidney Corp. Announces the Appointment of Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization

Now 24% undervalued

Investor sentiment improves as stock rises 15%

ProKidney Corp., Annual General Meeting, Jun 29, 2023

Investor sentiment improves as stock rises 19%

ProKidney (NASDAQ:PROK) Is In A Strong Position To Grow Its Business

Libbie McKenzie Resigns from Prokidney as Chief Medical Officer

ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of React for Late Stage 4 Diabetes-Related Chronic Kidney Disease

High number of new directors

ProKidney Corp. Appoints Glenn Schulman as Senior Vice President of Investor Relations

ProKidney Corp. Announces Board Appointments

ProKidney reports Q2 2022 results

ProKidney Corp. Appoints Kerry Cooper as Senior Vice President of Medical Affairs

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin